A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection

Trial Profile

A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Odalasvir (Primary) ; Sovaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 10 Jun 2014 According to an Achillion pharmaceuticals media release, the US FDA removed clinical hold on therapeutic trials with sovaprevir 200 mg in HCV patients and single dose healthy volunteer trials. But maintained a partial hold on multiple dose studies.
    • 14 Mar 2014 Results were presented at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 according to an Achillion Pharmaceuticals media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top